Skip to main content

Table 1 Clinico-pathological data of case and control subjects. (A) Tissue samples and (B) Plasma samples used for the study

From: Immunoproteomics approach revealed elevated autoantibody levels against ANXA1 in early stage gallbladder carcinoma

Subjects

Total number

Number of males

Number of females

Mean age (Years)

Age range (years)

(A) Tissue samples

Total GBC Cases

7

0

7

50.86

30–66

Stages

 GBC, Stage I

1

0

1

38

38

 GBC, Stage II

1

0

1

65

65

 GBC, Stage IIIA

5

0

5

50.6

30–66

Histological grade

 Well-differentiated (G1)

1

0

1

–

–

 Moderately-differentiated (G2)

4

0

4

–

–

 Poorly-differentiated (G3)

2

0

2

–

–

(B) Plasma samples

Total GBC Cases

52

10

42

50.88

22–78

Stages

 GBC, Stage I

6

1

5

39.66

22–47

 GBC, Stage II

6

1

5

52.16

34–66

 GBC, Stage III

17

2

15

52.76

30–66

 GBC, Stage IV

23

6

17

52.08

38–78

 Early Stages (I and II)

12

2

10

45.91

22–66

 Advanced stages (III and IV)

40

8

32

52.37

30–78

LN status

 LN negative

23

2

21

48.91

22–66

 LN positive

29

8

21

52.44

38–78

Histological grade

 Well-differentiated (G1)

5

0

5

–

–

 Moderately-differentiated (G2)

32

5

27

–

–

 Poorly-differentiated (G3)

15

2

13

–

–

Total Controls

89

28

61

40.89

20–72

GSD cases

48

13

35

43.06

20–72

Healthy group

41

15

26

38.36

24–59

  1. GBC Gallbladder carcinomas, GSD Gallstone disease, LN Lymph node